Jubilant Pharmova Limited

Jubilant Pharmova Limited

Jubilant Pharmova Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, received from M/s Alankit Assignments Limited, Registrar and Share Transfer Agent of the Company.

Jubilant Pharmova Limited

Jubilant Pharmova Limited has informed the Exchange about the submission of copies of newspaper advertisements relating to notice to shareholders regarding a special window for re-lodgement of transfer requests of physical shares, KYC updation and dematerialization of physical share certificates, and a second 100 days IEPF campaign.

Jubilant Pharmova Limited

Jubilant Pharmova Limited has received a rectification order from the jurisdictional Assessing Officer in Noida for Assessment Year 2019-20, disallowing a claim of forward losses of Rs. 53.37 crores. The company is in the process of filing an appeal before the Appellate Authority (National Faceless Appeal Centre) against the impugned order.

Jubilant Pharmova Limited

Jubilant Pharmova Limited has closed its trading window for insiders from July 1, 2026, until 48 hours after the announcement of its unaudited financial results for the quarter ending June 30, 2026.

Jubilant Pharmova Limited

Jubilant Pharmova Limited's subsidiary, Jubilant Generics Limited, has received a tentative approval from the USFDA for Pantoprazole Sodium Delayed Release Oral Suspension, 40 mg per packet. The approval is subject to the expiry of the patent covering the currently listed Reference Listed Drug (RLD) in December 2026.

Jubilant Pharmova Limited

Jubilant Pharmova Limited has received a rectification order from the Income Tax Department for its wholly-owned subsidiary Jubilant Generics Limited, reducing tax adjustments from Rs. 107.89 crs to Rs. 42.41 crs for Assessment Year 2023-24.

Jubilant Pharmova Limited

Jubilant Pharmova Limited has announced the completion of a USFDA inspection at its Jubilant HollisterStier LLC (JHS) contract manufacturing facility in Spokane, Washington, USA. The inspection of the CMO business concluded on June 17, 2026. While the company confirmed the inspection's completion, it has not yet disclosed the specific outcome, such as any observations or regulatory actions. This update signifies a key regulatory milestone for its US operations, with investors awaiting further details on the inspection's findings.